These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27664801)

  • 1. Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?
    Metsu D; Seraissol P; Delobel P; Cinq-Frais C; Cuzin L; Izopet J; Chatelut E; Gandia P
    Fundam Clin Pharmacol; 2017 Apr; 31(2):245-253. PubMed ID: 27664801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
    Gervasoni C; Meraviglia P; Minisci D; Ferraris L; Riva A; Landonio S; Cozzi V; Charbe N; Molinari L; Rizzardini G; Clementi E; Galli M; Cattaneo D
    PLoS One; 2015; 10(4):e0123670. PubMed ID: 25875091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
    Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
    HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.
    Ray JE; Marriott D; Bloch MT; McLachlan AJ
    Br J Clin Pharmacol; 2005 Sep; 60(3):291-9. PubMed ID: 16120068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.
    Smith DE; Jeganathan S; Ray J
    HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
    Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
    Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
    Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
    Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
    Colella E; Cattaneo D; Galli L; Baldelli S; Clementi E; Galli M; Lazzarin A; Castagna A; Rusconi S; Spagnuolo V
    New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment.
    Florent A; Gandia P; Seraissol P; Chatelut E; Houin G
    Ther Drug Monit; 2014 Dec; 36(6):752-8. PubMed ID: 24819971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
    Metsu D; Toutain PL; Chatelut E; Delobel P; Gandia P
    J Antimicrob Chemother; 2017 Sep; 72(9):2407-2409. PubMed ID: 28595364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
    Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
    Else LJ; Jackson V; Brennan M; Back DJ; Khoo SH; Coulter-Smith S; Lambert JS
    HIV Med; 2014 Nov; 15(10):604-10. PubMed ID: 24825070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
    Rodríguez-Nóvoa S; Martín-Carbonero L; Barreiro P; González-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS; 2007 Jan; 21(1):41-6. PubMed ID: 17148966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.